

Annual Report
Division of Clinical Epidemiology
Department of Medicine - Jewish General Hospital
January 1 - December 31, 2019

SUMMARY

1. Research and publications:

Total of new funding awarded this year: \$994,424.00. A combined total of 44 publications were published in 2019 by Dr. Samy Suissa, Dr. Kristian Filion and Dr. Antonios Douros.

Suissa, Samy

Dr. Samy Suissa is the Principal Investigator of the Canadian Network on Observational Drug Effect Studies (CNODES), and oversees funding of \$17.5 million received from CIHR for this network. CNODES assembles the top pharmacoepidemiologists in the country and uses a collaborative, population-based approach, exploiting existing healthcare databases across the country and using sophisticated, cutting edge and powerful analytical methods to rapidly evaluate the risks and benefits of medications on the health of Canadians.

Dr. Suissa's research is in pharmacoepidemiology which involves studying the risks and benefits of medications at the within the population at large. He specializes in the exploitation of existing computerized health databases to rapidly evaluate these risks. He has developed, and published extensively on, new methods of data analysis and study design that allow more rapid and accurate assessments of drug safety. He has conducted pharmacoepidemiological studies of several medications used for the treatment of chronic diseases, including asthma and COPD, cardiovascular and rheumatic diseases, and women's health issues. He has lectured extensively throughout the world, and is the author of over 500 peer-reviewed research papers published in scientific journals.

Filion, Kristian

Dr. Filion was awarded four grants in 2019 by the CIHR:

1. Cannabis and impaired driving: a knowledge synthesis. (Co-Investigator – Project Grant) -
2. Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease (Co-Investigator - Project Grant)
3. Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes (Co-Investigator - Project Grant)
4. A systematic review of interventions for the opioid crisis: examining approaches in a Canadian context and vulnerable sub-populations (Co-Investigator - Operating Grant: Evaluation of Interventions to Address the Opioid Crisis)

In 2019, Dr. Filion had 15 articles published or in press (5 as first or senior author). He has 25 submitted manuscripts (12 as first or senior).

Douros, Antonios

Dr. Douros was awarded three project grants (2 as Principal Investigator) in 2019 by the Canadian Institutes of Health Research (CIHR):

1. Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes (Principal Investigator)
2. Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease (Principal Investigator)
3. A personalized dynamic blood pressure control plan for cardiovascular disease prevention

among patients with hypertension (Co-Applicant)

He was also awarded a research grant in 2019 by the Lady Davis Institute

1. Drug effectiveness and safety in vulnerable populations (Principal Investigator)

In 2019, Dr. Douros had 11 articles published (5 as first author and 3 as senior author) including publications in high-impact journals such as the European Heart Journal (IF: 24.889), Diabetes Care (2x; IF: 15.270) and Neurology (IF: 8.689). Moreover, 2 of his publications were the subject of editorials.

2. Teaching and learning (undergraduate and graduate):

Suissa, Samy

Dr. Samy Suissa leads the Pharmacoepidemiology Summer Program in the Department of Epidemiology and Biostatistics which holds 4 courses each summer and in which he himself teaches the Advanced Pharmacoepidemiology course. He is currently supervising or co-supervising 2 PhD students, 1 MSc student and 1 Post-doctoral fellow:

Student Supervision 2019 (Samy Suissa)

- Mr. Farzin Khosrow-Khavar (PhD in Epidemiology) 2013-2019
- Ms. Tanja Tran (PhD in Epidemiology) 2014-
- Dr. Henok Tadesse Ayele (Postdoctoral Fellow) 2016-
- Mr. Anirudh Bakshi (MSc in Epidemiology) 2019-

Filion, Kristian

Dr. Kristian Filion teaches in the medical school and in the Department of Epidemiology, Biostatistics, and Occupational Health. In the Department of Epidemiology, Biostatistics, and Occupational Health, Dr. Filion was the instructor in the course entitled “Knowledge Synthesis” (3 credits). He was also the co-instructor for the course entitled “Intermediate Pharmacoepidemiology” (2 credits). He was a Guest Lecturer in the following courses: Pharmacoepidemiologic Methods – EPIB 639 (1.5 hours); Population Health and Epidemiology – PPHS 501 (1.5 hours).

In 2019, Dr. Filion supervised 1 PhD Student, 4 MSc student in epidemiology, 1 endocrinology fellow in research, and 5 post-doctoral fellows.

2019 Student Supervision (Kristian Filion):

- Dr. Azar Mehrabadi (Post-doctoral fellow) 2015-2019
- Dr. Henok Tadesse Ayele (Post-doctoral fellow) 2016-Present
- Sarah Yoon (MSc in Epidemiology) 2017-2019
- Linda Ou (MSc in Epidemiology) 2017-2019
- Stephanie Larose (MSc in Epidemiology) 2019-Present
- Nehal Islam (MSc in Epidemiology) 2019-Present
- Vanessa Brunetti (PhD in Epidemiology) 2017-Present
- Dr. Ya Hui Yu (Post-doctoral fellow) 2018-Present
- Dr. Tianze Jiao (Post-doctoral fellow) 2018-Present
- Dr. Reem Masarwa (Post-doctoral fellow) 2018-Present
- Dr. Stephanie Aloe (Endocrinology Fellow) 2018-2019

He is a member of 6 doctoral students' thesis committees.

Douros, Antonios

Dr. Antonios Douros has 2 degrees awarded (MD, Dr.med.). He is an Assistant Professor (Research) in the Department of Medicine (Division Clinical Epidemiology) and an Associate Member in the Department of Epidemiology, Biostatistics, and Occupational Health at McGill University. Dr. Douros taught the Small Group Sessions “Circumcision and HIV prevention”, “Interpreting diagnostic tests” (2), “Principles of screening” (2), “Lung cancer, smoking, case-control and cohort studies”, “Cardiovascular disease and randomized controlled trials” (2), and “Statistics for clinicians” in the M.D. C.M. Program. He was also responsible for the concept, syllabus, and teaching of the 1-credit course “EPIB 662 Pharmacological Basis of Pharmacoepidemiology” in the MSc and PhD Epidemiology Programs. Finally, he co-taught the 2-credit course “EPIB 661 PE III: Advanced Pharmacoepidemiology” of the Summer Session in Epidemiology and Biostatistics.

In 2019, Dr. Douros mentored three PhD candidates and one Postdoctoral Research Fellow.

3. Involvement in the community:

Suissa, Samy

Internal

- Chair, PhD Epidemiology Comprehensive Exam Committee, Department of Epidemiology and Biostatistics, McGill University, 2019-
- Member, LDI Scientific Director Search Committee, Lady Davis Institute, Jewish General Hospital
- Member, PhD Epidemiology Comprehensive Exam Committee, Department of Epidemiology and Biostatistics, McGill University, 2018-2019
- Member, Pharmacoepidemiology Program Ad-Hoc Committee, Department of Epidemiology and Biostatistics, McGill University, 2018-
- Member, Student Awards Ad-Hoc Committee, Department of Epidemiology and Biostatistics, McGill University, 2018-
- Member, Search Committee Meeting, CAS (Research) Assistant Professor in Clinical Epidemiology, Department of Medicine, McGill University, 2017
- Member, SPGH Director Search Committee, Department of Medicine, McGill University 2017
- Member, PhD Epidemiology Admissions Committee, Department of Epidemiology, Biostatistics, McGill University, 2017
- Member, Departmental Tenure Committee, Department of Epidemiology, Biostatistics, McGill University, 2016-

External

Advisory Board Committee

- Scientific Advisory Board Member, The Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Université 2019-
- Member, Multi-Regional Clinical Trials Center, Proactive Safety Surveillance Project, Harvard University, 2019-
- Advisory Board Member, RCT replication project Brigham and Women’s, Hospital, Harvard University, 2017-
- International Advisory Board Member, Unicancer, 2016-
- Member, Drug Safety and Effectiveness Network (DSEN) Interim Science Advisory Committee (ISAC), Canadian Institutes for Health Research, 2011-

Reviewer Committee

- Advisor, Editorial Board, Journal of Chronic Obstructive Pulmonary Disease, 2019-
- Member, Editorial Board, Chest, 2015-2019

- Member, Editorial Board, Rambam Maimonides Medical Journal, 2012-
- Statistician/Epidemiologist Reviewer, The Lancet Respiratory Medicine, 2012-
- Member, Editorial Board, Multidisciplinary Respiratory Medicine, 2011-
- International Advisory Board Member, Statistical Advisor, European Respiratory Journal 2007-

Filion, Kristian

Internal:

- Lady Davis Institute/TD Studentship Review Committee, Lady Davis Institute, Montreal, Quebec, 2017-Present
- McGill Pharmacoepidemiology Working Group, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Faculty Co-Facilitator, 2017-Present
- Ad-hoc Working Group for Pharmacoepidemiology Programs, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Member, 2017-Present
- Admissions Committee, Epidemiology PhD Program, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Member, 2017-Present
- Pharmacoepidemiology Option, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, PhD Advisor, 2016-Present
- Joint MD-PhD Program Advisory Committee, Faculty of Medicine, McGill University, Montreal, Quebec, Member, 2015-Present
- McGill Pharmacoepidemiology Journal Club, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Faculty Co-Facilitator, 2011-Present

External:

- Scientific Advisory Committee, Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT) Initiative, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard University, Member, 2019 - Present
- Permanent Scientific Committee for the Evaluation of Medications, *Institut national d'excellence en santé et en services sociaux* (INESSS), Member, 2018-Present
- Health Research Training A – PhD, Post-Doctoral Fellowships, Canadian Institutes of Health Research. 2018-Present
- College of Reviewers, Canadian Institutes of Health Research, 2017- Present
- Scientific Committee, AstraZeneca Chair in Respiratory Health, University of Montreal, Member, 2017-Present
- Scientific Advisory Committee, Drug Safety and Effectiveness Network, Member, 2017-Present
- Canadian Network for Observational Drug Effect Studies (CNODES), Member, 2011-Present
- Evaluating the Efficacy of E-Cigarette use for Smoking Cessation (E3) Trial Steering Committee, Member, 2014-Present

Douros, Antonios

1. **Lady Davis Institute Internal Grant Review Program:** Review Committee Member (5) including Review Committee Chair (3)
2. **Ad-hoc Reviewer** for 16 peer-reviewed journals
3. **Conferences:**
 - a. **Abstract Reviewer**
 - Apr 2019: 3. Symposium on Pharmacoepidemiology, Evros Pharmacists Association, Alexandroupoli, Greece (10 hours)
 - Aug 2019: 35. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, International Society for Pharmacoepidemiology (ISPE), Philadelphia, PA (10 hours)

b. Poster Session Judge

Mar 2019: 15. Annual Student Research Day of the Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC (1 hour)

c. Moderator

Apr 2019: Methodology of pharmacoepidemiologic studies (oral presentations)
3. Symposium on Pharmacoepidemiology, Evros Pharmacists Association, Alexandroupoli, Greece (2 hours)

4. Partnerships:

Suissa, Sammy

- Summer Course on Pharmacoepidemiology and Drug Safety. Utrecht, Netherlands.
- Research and training collaboration, Clalit Health, Israel

5. Milestones:

N/A

6. New hires, promotions, and retirements:

Dr. Suissa was named Distinguished James McGill Professor of Epidemiology and Biostatistics, and Medicine, at McGill University.

Dr. Filion was granted tenure and promoted to Associate Professor.

Dr. Douros was appointed Assistant Professor in the Department of Medicine and Associate Member in the Department of Epidemiology, Biostatistics and Occupational Health at McGill University. He was appointed Investigator at the Lady Davis Institute of the Jewish General Hospital.

7. Honors, awards and prizes:

Suissa, Sammy

Distinguished James McGill Professor, McGill University (2019-Present)

Fellow – Royal Society of Canada, Life Sciences Division of the Academy of Science (2018-Present)

Fellow – Distinction, Canadian Academy of Health Science (2013-Present)

James McGill Professor – McGill University (2005-2019)

Filion, Kristian

William Dawson Scholar Award, McGill University (2018-2023)

Fellow of the American Heart Association (2012-Present)

Douros, Antonios

Honours:

Paper of the Quarter (Apr 2019) Institute of Biometry and Clinical Epidemiology
Charité-Universitätsmedizin Berlin, Berlin, Germany

Article title: Control of blood pressure and risk of mortality in a cohort of older adults: The Berlin Initiative Study. Eur Heart J. 2019 Jul; 40(25): 2021-2028.

Paper of the Month (Jul 2019) Lady Davis Institute for Medical Research - Jewish General Hospital, Montreal, QC

Article title: Control of blood pressure and risk of mortality in a cohort of older adults: The Berlin Initiative Study. Eur Heart J. 2019 Jul; 40(25): 2021-2028.

Editor's Choice (Jul 2019) European Heart Journal
Article title: Control of blood pressure and risk of mortality in a cohort of older adults: The Berlin Initiative Study. Eur Heart J. 2019 Jul; 40(25): 2021-2028.
Best Reviewer 2018 (Aug 2019) Pharmacoepidemiology and Drug Safety

Awards:

Incentive for High-Impact Publications (Feb 2019) Charité-Universitätsmedizin Berlin, Berlin, Germany

Article title: Control of blood pressure and risk of mortality in a cohort of older adults: The Berlin Initiative Study. Eur Heart J. 2019 Jul; 40(25): 2021-2028.

Incentive for High-Impact Publications (Jul 2019) Charité-Universitätsmedizin Berlin, Berlin, Germany

Article title: Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. Diabetes Care 2019 Aug; 42(8): 1496-1503.

8. Fundraising:

N/A

SECTION I - DIVISION STATUS UPDATE

1. Mission and objectives of the Division

The Division of Clinical Epidemiology, a recent addition to the JGH Department of Medicine includes three members, Drs Kristian Fillion, Antonios Douros and Dr Samy Suissa, the Chief of the Division.

2. A nominative list of academic staff, their academic rank

Dr. Kristian Fillion – Associate Professor - active

Dr. Antonios Douros – Assistant Professor - active

Dr. Samy Suissa – Professor - active

SECTION II - GRANTS, PUBLICATIONS, AND SERVICE OUTSIDE OF MCGILL

1. Grants and awards received

[Suissa, Samy](#)

Source: Canadian Institutes for Health Research

Title: Canadian Network for Observational Drug Effect Studies (CNODES)-renewal.

Amount/Year: \$17,500,000/2016-21

Role: Principal Investigator

Source: Canadian Institute for Health Research - Rapid Funding for Drug Safety and Effectiveness Network (DSEN) Targeted Research Grant.

Title: Development of a Common Data Model across selected CNODES sites

Amount/Year: \$250,000/2016-2018

Role: Co-Principal Investigator

Source: Health Brains for Healthy Living, McGill University

Title: A personalized approach to depression care: Discovering adaptive treatment strategies

Amount/Year: \$65,847.50/2018-20

Role: Co-Investigator **PI:** Erica Moodie

Source: Canadian Institutes for Health Research

Title: Secondary Data Analysis for Cancer Prevention and Control. Onset of cancer after an IBD diagnosis: potential impact on screening Strategies.

Amount/Year: \$144,00/2018-20

Role: Co-Investigator **PI:** Paul Brassard

Source: Canadian Institute for Health Research, Foundation Scheme 2014

Title: Statistical Methods in Pharmacoepidemiology and Perinatal Epidemiology.

Amount/Year: \$1,071.717/2015-22

PI: Robert Platt **Role:** Program Expert

Filion, Kristian

Grants and awards received

Source: Canadian Institutes of Health Research.

Title: Cannabis and impaired driving: a knowledge synthesis. (Project Grant Competition)

Amount/Year: \$114,750/2019-2021

Role: Co-Investigator, **PI:** Mark J. Eisenberg

Source: Canadian Institutes of Health Research.

Title: Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease (Project Grant Competition)

Amount/Year: \$225,676/2019-2022

Role: Co-Investigator, **PI:** Antonios Douros

Source: Canadian Institutes of Health Research.

Title: Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes (Project Grant Competition)

Amount/Year: \$149,176/2019-2021

Role: Co-Investigator, **PI:** Antonios Douros

Source: Canadian Institutes of Health Research.

Title: A systematic review of interventions for the opioid crisis: examining approaches in a Canadian context and vulnerable sub-populations (CIHR Operating Grant: Evaluation of Interventions to Address the Opioid Crisis)

Amount/Year: \$99,970/2019-2020

Role: Co-Investigator, **PI:** Mark J. Eisenberg

Source: Canadian Institutes of Health Research.

Title: Levothyroxine for the treatment of subclinical hypothyroidism in pregnancy: a population-based assessment (Project Grant Competition)

Amount/Year: \$175,950/2018-2020

Role: Principal Investigator

Source: Canadian Institutes of Health Research.

Title: Evaluating the Efficacy of E-Cigarette use for Smoking Cessation (E3) Trial Extension (Project Grant Competition)

Amount/Year: \$267,750/2018-2020

Role: Co-Investigator, **PI:** Mark J. Eisenberg

Source: Canadian Institutes of Health Research.

Title: Legalization of recreational cannabis use in Canada: a knowledge synthesis (Catalyst Grant: Population Health Intervention Research on Legalization of Cannabis)

Amount/Year: \$100,000/2018-2019

Role: Co-Investigator, **PI:** Mark J. Eisenberg

Source: Canadian Institutes of Health Research.

Title: Pregnancy complications and the risk of subsequent cardiovascular disease (Personalized Medicine Catalyst Competition)

Amount/Year: \$200,000/2017-2019

Role: Principal Investigator

Source: Canadian Institutes of Health Research.

Title: Tramadol and the risk of adverse cardiovascular events: a population-based study (Project Grant)

Amount/Year: \$175,950/2017-2019

Role: Principal Investigator

Source: Canadian Institutes of Health Research.

Title: Canadian Network for Observational Drug Effect Studies (DSEN Collaborating Centre for Observational Studies)

Amount/Year: \$17,500,000/2016-2021

Role: Co-Investigator **PIs:** Samy Suissa PhD, Colin R. Dormuth ScD, David A. Henry MD, Robert W. Platt PhD, Ingrid Sketris PharmD

Source: Canadian Institutes of Health Research.

Title: Improving long term outcomes after venous thromboembolism (VTE) (Foundation Scheme)

Amount/Year: \$2,050,825/2015-2022

Role: Project Expert **PI:** Susan Kahn

Source: Canadian Institutes of Health Research.

Title: Evaluating the efficacy of e-cigarette use for smoking cessation (E3) Trial (Operating Grant)

Amount/Year: \$829,350/2014-2019

Role: Project Expert **PI:** Mark J. Eisenberg

[Douros, Antonios](#)

Source: Canadian Institutes of Health Research (CIHR) - Project Grant

Title: A personalized dynamic blood pressure control plan for cardiovascular disease prevention among patients with hypertension

Amount/Year: C\$191,250/Apr 2020 - Mar 2022

Role: Co-Investigator (PI: Kristian Filion)

Source: Canadian Institutes of Health Research (CIHR) - Project Grant
Principal Investigator: **Douros A.** Co-applicants: Filion KB, Platt RW, Renoux C.
Title: Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes
Amount/Year: C\$149,176/Oct 2019 - Sep 2021
Role: Principal Investigator

Source: Canadian Institutes of Health Research (CIHR) - Project Grant
Title: Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease
Amount/Year: C\$225,676/ Oct 2019 - Sep 2022
Role: Principal Investigator

Source: Lady Davis Institute for Medical Research - Research Grant
Title: Drug effectiveness and safety in vulnerable populations
Amount/Year: C\$30,000/Jul 2019 - Jul 2022
Role: Principal Investigator

2. Scholarly works published in the 2019 calendar year:

[Samy Suissa](#)

1. Douros A, Renoux C, Yin H, Filion KB, **Suissa S**, Azoulay L. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation. *Am J Med.* 2019 Feb;132(2):191-199.
2. Montastruc F, Renoux C, Dell'Aniello S, Simon TA, Azoulay L, Hudson M, **Suissa S**. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. *Rheumatology (Oxford).* 2019 Apr 1;58(4):683-691.
3. Platt RW, Platt R, Brown JS, Henry DA, Klungel OH, **Suissa S**. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. *Pharmacoepidemiol Drug Saf.* 2019 Jan 15 (epub ahead of print).
4. **Suissa S**, Ariel A. Triple therapy trials in COPD: only for the right patient. *Eur Respir J* 2019 18;53(4).
5. **Suissa S**, Dell'Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. *Chest* 2019 Jun;155(6):1158-1165.
6. Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, **Suissa S**, Brassard P. Risk of malignant cancers in inflammatory bowel disease. *J Crohns Colitis.* 2019 Sep 27;13(10):1302-1310.
7. Lin HD, Lai CL, Dong YH, Tu YK, Chan KA, **Suissa S**. Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study. *Drugs Real World Outcomes.* 2019;6(3):93-104.
8. Montastruc F, Renoux C, Hudson M, Dell'Aniello S, Simon TA, **Suissa S**. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. *Semin Arthritis Rheum.* 2019 Jun;48(6):1053-1058.
9. **Suissa S**. Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias? *Eur Respir J.* 2019 Feb;53(2). Epub ahead of print.
10. Schneeweiss S, **Suissa S**. Discussion of Schuemie et al: "A plea to stop using the case-control design in retrospective database studies". *Stat Med.* 2019 Sep 30;38(22):4209-4212.

11. Filion KB, Douros A, Azoulay L, Yin H, Yu OH, **Suissa S**. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. *Br J Clin Pharmacol*. 2019;85(10):2378-2389..
12. Hudson M, Dell'Aniello S, Shen S, Simon TA, Ernst P, **Suissa S**. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. *Rheumatology (Oxford)*. 2019 Sep 3.
13. Sultana J, Trotta F, Addis A, Brown JS, Gil M, Menniti-Ippolito F, Milozzi F, **Suissa S**, Trifirò G. Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. *Drug Saf*. 2019 Oct 22. doi: 10.1007/s40264-019-00871-w. [Epub ahead of print].
14. Simon TA, Boers M, Hochberg M, Baker N, Skovron ML, Ray N, Singhal S, **Suissa S**, Gomez-Caminero A. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. *Arthritis Res Ther*. 2019 Nov 8;21(1):228.
15. **Suissa S**, Dell'Aniello S, Gonzalez AV, Ernst P. Inhaled corticosteroid use and the incidence of lung cancer in COPD. *Eur Respir J*. 2019 Nov 19. pii: 1901720.
16. **Suissa S**, Dell'Aniello S, Ernst P. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice. *Chest*. 2019 Nov 22. pii: S0012-3692(19)34225-4.
17. **Suissa S**. Improving the Efficiency of Randomized Trials: The DYNAGITO Example. *COPD*. 2019 Dec 3:1-3.
18. **Suissa S**, Hudson M, Dell'Aniello S, Shen S, Simon TA, Ernst P. Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study. *Semin Arthritis Rheum*. 2019 Dec;43(3):366-372.

Kristian Filion

1. Grandi SM, **Filion KB**, *Yoon S, *Ayele HT, Doyle CM, Hutcheon JA, Smith GN, Gore GC, Ray JG, Nerenberg K, Platt RW. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. *Circulation* 2019;139:1069-1079.
2. Windle SB, Wade K, **Filion KB**, Kimmelman J, Thombs BD, Eisenberg MJ. Potential harms from legalization of recreational cannabis use in Canada: a commentary. *Can J Pub Health* 2019;110:222-226.
3. Kahn SR, Diendéré G, Morrison DR, Piché A, **Filion KB**, Klil-Drori AJ, Douketis JD, Emed J, Roussin A, Tagalakis V, Morris M, Geerts W. The effectiveness of interventions for the implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism: an abridged Cochrane systematic review and meta-analysis of Randomized Controlled Trials (RCT). *BMJ Open* 2019;e024444. doi: 10.1136/bmjopen-2018-024444.
4. *Garfinkle R, Savage P, Boutros M, Landry T, Reynier P, Morin N, Vasilevsky CA, **Filion KB**. Incidence and predictors of postoperative ileus after loop ileostomy closure: a systematic review and meta-analysis. *Surg Endosc* 2019;33:2430-2443.
5. *Lefebvre C, Zappitelli M, Hindie J, Platt RW, **Filion KB**. Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. *Clin Kid J* 2019 May 20. sfz054, <https://doi.org/10.1093/ckj/sfz054>.
6. Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, **Filion KB**, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttman A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. Directives pour l'évaluation des études réalisées à partir des données de santé collectées en routine en pharmacoépidémiologie : RECORD-PE (REporting of studies Conducted using Observational Routinely-collected health

- Data for pharmacoepidemiology) CMAJ 2019; 24;191:E689-E708. [published in French]
7. *Douros A, Durand M, Doyle CM, *Yoon S, Reynier P, **Filion KB**. Comparative effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis of observational studies. *Drug Saf* 2019;42:1135-1148.
 8. Douros A, Rouette J, Yin H, Yu OHY, **Filion KB**, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. *Diabetes Care* 2019 Aug;42(8):1496-1503.
 9. †Khosrow-Khavar F, †Kurteva S, Cui Y, **Filion KB**, Douros A. Opioids and the risk of infection: a critical appraisal of the pharmacologic and clinical evidence. *Expert Opin Drug Metab Toxicol*. 2019; 15:565-575.
 10. **Filion KB**, Douros A, Azoulay L, Yin H, Yu O, Suissa S. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: a population-based cohort study. *Br J Clin Pharmacol* 2019; 85:2378-2389.
 11. **Filion KB**, Yu OH. Sodium-glucose cotransporter 2 inhibitors and severe urinary tract infections: reassuring real-world evidence. *Ann Intern Med* 2019; 171(4):289-290. [Invited Editorial]
 12. Oh IS, **Filion KB**, Jeong HE, Shin JY. An empirical assessment of immeasurable time bias in the setting of nested case-control studies: statins and all-cause mortality among patients with heart failure. *Pharmacoepidemiol Drug Saf* 2019;28: 1318-1327.
 13. **†Lancione S, **†Wade K, Windle SB, **Filion KB**, Thombs BD, Eisenberg MJ. Non-medical cannabis in North America: an overview of regulatory approaches. *Public Health* 2019 Oct 7;178:7-14.
 14. Huang TY, Welch EC, Shinde MU, Platt RW, **Filion KB**, Azoulay L, Maro MC, Platt R, Toh S. Reproducing Protocol-based Studies Using Parameterizable Tools - Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. *Clin Pharmacol Ther* 2019 Oct 20. doi: 10.1002/cpt.1698. [Epub ahead of print].
 15. *Garfinkle R, **Filion KB**, Bhatnagar S, Sigler G, Banks A, Letarte F, Liberman S, Brown CJ, Boutros M. Prediction model and web-based risk calculator for postoperative ileus after loop ileostomy closure. *Br J Surg*. 2019 Nov;106(12):1676-1684.

[Douros Antonios](#)

1. **Douros A**, Renoux C, Yin H, Filion KB, Suissa S, Azoulay L. Concomitant use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with non-valvular atrial fibrillation. *Am J Med*. 2019 Feb; 132(2); 191-199.e12.
2. Sommet A, Benevent J, Rousseau V, Chebane L, **Douros A**, Montastruc JL, Montastruc F. What fluoroquinolones have the highest risk of aortic aneurysms? A case/non-case study in VigiBase®. *J Gen Intern Med*. 2019 Apr; 34(4): 502-503.
3. **Douros A***, Toelle M*, Ebert N, Gaedeke J, Huscher D, Kreutz R, Kuhlmann M, Martus P, Mielke N, Schneider A, Schuchardt M, van der Giet M, Schaeffner E. (*shared first authorship) Control of blood pressure and risk of mortality in a cohort of older adults: The Berlin Initiative Study. *Eur Heart J*. 2019 Jul; 40(25): 2021-2028.
Accompanying editorial: Ewen S, Mahfoud F, Böhm M. Blood pressure targets in the elderly: many guidelines, much confusion. *Eur Heart J*. 2019 Jul; 40(25): 2029-2031.
4. Khosrow-Khavar F, Kurteva S, Cui Y, Filion KB, **Douros A**. Opioids and the risk of infection: a critical appraisal of the pharmacologic and clinical evidence. *Expert Opin Drug Metab Toxicol*. 2019 Jul; 15(7): 565-575.
5. **Douros A**, Rouette J, Yin H, Filion KB, Yu OH, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. *Diabetes Care*. 2019 Aug; 42(8): 1496-1503.

6. Abrahami D, **Douros A**, Yin H, Yu OH, Azoulay L. Sodium-glucose co-transporter 2 inhibitors and the risk of fractures in patients with type 2 diabetes. *Diabetes Care*. 2019 Sep; 42(9): e150-e152.
 7. **Douros A**, Dell'Aniello S, Dehghan G, Boivin JF, Renoux C. Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: a cohort study. *Neurology*. 2019 Sep; 93(10): e1010-e1020.
 8. Kreutz R, Algharably EAH, **Douros A**. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. *J Hypertens*. 2019 Oct; 37(10): 1950-1958.
Accompanying editorial: Schlaich MP, Nolde J, Carnagarin R, Kiuchi MG. Diuretics and skin cancer: should a common prescription come with advice to avoid sun exposure? *J Hypertens*. 2019 Oct; 37(10): 1961-1962.
 9. **Douros A**, Durand M, Doyle CM, Yoon S, Reynier PM, Filion KB. Comparative effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. *Drug Saf*. 2019 Oct; 42(10): 1135-1148.
 10. Filion KB, **Douros A**, Azoulay L, Yin H, Yu OH, Suissa S. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. *Br J Clin Pharmacol*. 2019 Oct; 85(10): 2378-2389.
 11. Khosrow-Khavar F, Kurteva S, **Douros A**. Re: Metformin use and gastric cancer risk in diabetic patients after *Helicobacter pylori* eradication. *J Natl Cancer Inst*. 2019 Oct; 111(10): 1107-1108.
3. **Academic and community engagement service outside of McGill by individual members of the unit**